{"id":654943,"date":"2023-06-09T13:14:01","date_gmt":"2023-06-09T13:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654943"},"modified":"2023-06-09T13:14:01","modified_gmt":"2023-06-09T13:14:01","slug":"congenital-diarrheal-disorders-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/congenital-diarrheal-disorders-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar_654943.html","title":{"rendered":"Congenital Diarrheal Disorders Clinical Trials | A Drug Pipeline Analysis Report 2023 Companies &#8211; Stempeutics, Angiocrine Bioscience, Carephar"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Congenital Diarrheal Disorders Clinical Trials | A Drug Pipeline Analysis Report 2023 Companies - Stempeutics, Angiocrine Bioscience, Carephar \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Congenital Diarrheal Disorders Clinical Trials | A Drug Pipeline Analysis Report 2023 Companies - Stempeutics, Angiocrine Bioscience, Carephar \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s,\u201cComplicated Intra-Abdominal Infections \u2013 Pipeline Insights, 2023,\u201d report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Complicated Intra-Abdominal Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">(Nevada, Las Vegas United States), &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/congenital-diarrheal-disorders-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Congenital Diarrheal Disorders Pipeline Insight, 2023<\/a><\/strong>&#8221; report by DelveInsight outlays comprehensive insights of the present clinical development scenario and growth prospects across the Congenital Diarrheal Disorders market. A detailed picture of the Congenital Diarrheal Disorders pipeline landscape is provided, which includes the disease overview and Congenital Diarrheal Disorders treatment guidelines.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/congenital-diarrheal-disorders-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Takeaways from the Congenital Diarrheal Disorders Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Congenital Diarrheal Disorders companies developing novel drug candidates to improve the Congenital Diarrheal Disorders treatment landscape include Jaguar Health and others<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Congenital Diarrheal Disorders pipeline therapies in various stages of development include Mytesi and others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Congenital Diarrheal Disorders Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Congenital diarrheal disorders (CDDs) are a group of inherited enteropathies with a typical onset early in life. Infants with these disorders have frequently chronic diarrhea of sufficient severity to require parenteral nutrition. For most CDDs, the disease gene is known and molecular analysis may contribute to an unequivocal diagnosis. We review CDDs on the basis of the genetic defect, focusing on the significant contribution of molecular analysis in the complex, multistep diagnostic workup.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/1a61da520b558c7e6a9835835136ac59.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Congenital Diarrheal Disorders Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mytesi: Jaguar Health<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Congenital Diarrheal Disorders Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Alpha1 Antitrypsin Deficiency Companies: &nbsp;Jaguar Health and many others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Congenital Diarrheal Disorders&nbsp; Pipeline Therapies: Mytesi and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Find out more about the Congenital Diarrheal Disorders treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/congenital-diarrheal-disorders-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Congenital Diarrheal Disorders Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Congenital Diarrheal Disorders Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Congenital Diarrheal Disorders Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Congenital Diarrheal Disorders Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Congenital Diarrheal Disorders Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Congenital Diarrheal Disorders Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Congenital Diarrheal Disorders Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Congenital Diarrheal Disorders Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Congenital Diarrheal Disorders Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Congenital Diarrheal Disorders Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Congenital Diarrheal Disorders Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Congenital Diarrheal Disorders Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Congenital Diarrheal Disorders Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Congenital Diarrheal Disorders Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Congenital Diarrheal Disorders Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=congenital-diarrheal-disorders-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=congenital-diarrheal-disorders-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s,\u201cComplicated Intra-Abdominal Infections \u2013 Pipeline Insights, 2023,\u201d report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Complicated Intra-Abdominal Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/congenital-diarrheal-disorders-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar_654943.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-654943","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=654943"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654943\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=654943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=654943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=654943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}